Novel, Rapid Diagnostics for Veterinary Medicine

Novel, Rapid Diagnostics for Veterinary Medicine

Nuclease Probe Technologies’ NucAP™ culture plates
Nuclease Probe Technologies’ NucAP™ culture plates
Peanut the dog

Peanut
--NPT Company Mascot--


inoculated plate with no colonies at time zero but colonies after 8 hours.

(Laboratory-grown S. pseudintermedius applied to plate. Brightness of images is adjusted.)

inoculated plate with no colonies at time zero but colonies after 8 hours.

(Laboratory-grown S. pseudintermedius applied to plate. Brightness of images is adjusted.)

AVAILABLE PRODUCTS


AVAILABLE PRODUCTS


Don't wait days for Antibiotic Susceptibility Data from Reference Labs

Get Same-Day Results for canine pyoderma with NPT’s NucAP™ Pyoderma Tri-plates!


NucAP™ Pyoderma Tri-plate

NucAP™ Pyoderma Tri-plate (Clind/Ox)

  • Indications for use include dogs with clinical lesions resembling pyoderma (pustules and papules resembling bacterial folliculitis, and epidermal collarettes) and the cytological presence of cocci within the lesions.
  • The Clind/Ox version of the NucAP™ Pyoderma Tri-plate provides Clindamycin and Oxacillin antibiotic susceptibility results for key Gram-positive pathogens, including S. pseudintermedius.

Edvotek TruBlu™ 2 Blue/White Transilluminator

Blue light box (Edvotek TruBlu™ 2 Blue/White Transilluminator)


Watch the Full Procedure


More Information

Technology


A simple molecular probe for big infection problems

The Technology


A simple molecular probe for big infection problems

NPT has pioneered a new field of diagnostics that harnesses the enzymatic power of a category of biomarkers known as nucleases. The approach yields uncommon levels of sensitivity and specificity. Because signal generation only occurs if the biomarker is present in the specimen being tested, this approach results in higher signal-to-noise and fewer reagent-dependent artifacts than current methods such as the polymerase chain reaction (PCR) and immunoassays.

The molecular basis of the approach is illustrated in the figure on the right. Each nuclease probe consists of an oligonucleotide (shown in gray) flanked with a fluorophore (F) and a quencher (Q). Upon contact with a disease-associated nuclease biomarker (shown in yellow), the nuclease probe is cleaved, resulting in separation of the quencher from the fluorophore and a consequent increase in fluorescence.

biosenor model, NPT Rapid Testing

Technical Papers

Applications


Applications


Building a Rich Pipeline

Building a Rich Pipeline

Bloodstream Detection of Pathogens

Bacterial Nucleases Provide Basis For Ultrasensitive Detection

Learn more

Pathogen Detection from Urine

Our technology can be used to identify infectious diseases like urinary tract infections

Learn more

Detecting Cancer Cells in Blood

Nuclease activities of cancer cells enables detection

Learn more

About NPT


Nuclease Probe Technologies was founded to solve one of the most basic problems in diagnostics—the need to rapidly detect diseases. Early detection enables veterinarians and physicians to make informed treatment decisions faster and achieve better outcomes for patients.

Leadership & Scientific Team

LinkedIn

Scientific Founder and Chief Executive Officer — James McNamara, Ph.D.


James McNamara, PhD

James founded NPT to commercialize rapid diagnostic applications based on the nuclease detection technology platform invented in his academic research program, and he has served as CEO since 2018. He is an inventor on several pending and issued patents that cover the platform and has authored twenty-five peer-reviewed scientific publications, including 8 studies involving the nuclease detection technology. His pursuit of the nuclease detection platform has been supported by over $2M in grants. James recruited a team of subject matter experts who provide NPT with complementary business and scientific expertise to develop the commercial potential of the technology. Since opening NPT’s R&D operation in the M2D2 startup incubator in Lowell, Massachusetts in 2019, James has overseen the development and commercialization of NPT’s NucAP™ Pyoderma Tri-plate, a nuclease detection-based veterinary diagnostic. James previously earned a BS in Chemical Engineering at the University of Virginia, a PhD in Neurobiology at Duke University and completed a post-doctoral fellowship in RNA-based therapeutics at Duke. Prior to opening NPT’s Massachusetts operations, he was a tenured Associate Professor in the Department of Internal Medicine at the University of Iowa.

LinkedIn

Director of Research and Development — Nodar Makharashvili, Ph.D.


Director or Research and Development — Nodar Makharashvili, Ph.D.

Nodar has led NPT’s R&D program since joining the company in 2019. He is an accomplished biochemist with extensive experience in structural biology, and molecular diagnostics assay development, optimization, and validation. He is an inventor on two NPT patent applications and has previously authored 11 scientific studies including 5 first-author publications. Upon joining NPT, Nodar spearheaded the development and expansion of the NucAP™ platform, including the advancement of the NucAP™Pyoderma Tri-plate, NPT’s first product. Prior to joining NPT, Nodar led a multi-disciplinary team developing a computational monoclonal antibody discovery platform at Macromoltek, an early-stage life science company in Austin, TX. He earned his Ph. D. at St. Louis University with a thesis in structural biology and completed a post-doctoral fellowship in cancer biology in the Howard Hughes Medical Institute at the University of Texas at Austin.

Scientific Advisory Board

LinkedIn

Blake W. Buchan, Ph.D.— Associate Director, Clinical Microbiology, Medical College of Wisconsin


Blake W. Buchan, PhD

Dr. Buchan is in charge of the education of residents in the Pathology residency program at MCW. He is the Associate Residency Program Director for Clinical Pathology, Course Director for the PGY-1 Molecular Pathology rotation, and attending faculty for the PGY-2 Microbiology rotation. In these roles he leads trainees in practical, didactic, and discussion sessions related to education in clinical microbiology and molecular diagnostics. Dr. Buchan serves in the clinical role of Associate Director for Clinical Microbiology and Molecular Diagnostics in which he oversees many aspects of the clinical microbiology laboratory including test interpretation, review of daily results, and council of technologists. In addition, he serve as Principal Investigator for numerous clinical trials involving new diagnostic assays for the identification of bacterial, viral and fungal pathogens

LinkedIn

Bradley Ford, MD, Ph.D.— Medical Director, Clinical Microbiology, University of Iowa Healthcare


Bradley Ford, MD, Ph.D.

Dr. Bradley Ford, MD PhD, is Director of Microbiology at the University of Iowa Hospitals and Clinics and a Member of the American Society of Microbiology, as well as a member of the Editorial Board of the Journal of Clinical Microbiology.  Dr. Ford is an author of over 53 peer-reviewed journal publications.  In his role as Director of Microbiology at the University of Iowa Hospitals and Clinics, Dr. Ford is responsible for all patient testing, training of physicians and laboratory staff, and oversight of microbiology laboratory operations.  Dr. Ford has evaluated and led the adoption of new microbiological methods for pathogen identification and antibiotic susceptibility testing including novel molecular devices.  Dr. Ford has served as the principal investigator on projects that evaluated the clinical efficacy of new methods for rapid identification and antibiotic susceptibility testing of bacteria present in blood cultures, as well as, other molecular methods for identifying genetic mechanisms of antibiotic resistance in bacteria.

Advisor

Senior Executive Advisor — Philippe Nore


Philippe Nore

Philippe is an experienced Startup CEO in the Life Sciences industry with a passion for driving the adoption of new products and technologies. Prior to NPT, he co-founded and led as CEO for several years MiNDERA, a MedTech company developing Next-Generation Skin Diagnostics & Analytics. Prior to MiNDERA Philippe was Senior International Business Leader at Roche Diagnostics where he held global P & L responsibility and launched several FDA-approved products. Philippe has held prior business consulting roles in the life sciences industry with Bain & Company a global management consulting firm, and for LEK Consulting, a world renown management and strategy consulting firm. Philippe is a proven general manager and business development expert in the Life Sciences industry with extensive US and international experience. Philippe has a demonstrated track record of developing and launching new businesses and a passion for driving the adoption of new products and technologies. Philippe holds a MSc. in chemistry from ESPCI (Paris) and an MBA from the Wharton School where he graduated as a Palmer Scholar.

Join our Team

Nuclease Probe Technologies is building a new class of diagnostic tools that harnesses the enzymatic potential of protein biomarkers to solve major problems in veterinary medicine and healthcare. We are looking for passionate, driven individuals who are interested in joining us in this pursuit. If this sounds like you, please drop us a note; we’d love to hear from you!

 

Nuclease Probe Technologies, Inc. is proud to be an Equal Opportunity Employer. Our goal is to have a diverse workforce. We do not discriminate on the basis of race, age, color, religion, national origin, gender, sexual orientation, gender identity or expression, veteran status or disability or any other status protected under federal, state or local law. All employment is decided on the basis of qualifications, merit, and business need.

Patents


United States patents licensed by Nuclease Probe Technologies include: 9,603,949; 10,619,219; 10,653,800; 11,155,882. Additional US patents owned or licensed by Nuclease Probe Technologies are pending.

United States patents licensed by Nuclease Probe Technologies include: 9,603,949; 10,619,219; 10,653,800; 11,155,882. Additional US patents owned or licensed by Nuclease Probe Technologies are pending.

News


Nuclease Probe Technologies raises $500,000 from Breakout Labs to Support Development of Rapid Antibiotic Susceptibility Testing for Bloodstream Infections

Nuclease Probe Technologies raises $500,000 from Breakout Labs to Support Development of Rapid Antibiotic Susceptibility Testing for Bloodstream Infections

March 5, 2019 08:00 AM Eastern Daylight Time
Lowell, MA—Nuclease Probe Technologies, Inc., a company pioneering a precision medicine approach to matching patients with the most effective antibiotics to treat deadly bloodstream infections, announces the investment by Breakout Labs...
Read More

Contact Us


Nuclease Probe Technologies, Inc.

110 Canal Street, 4th Floor
c/o M2D2
Lowell, MA 01852

For business development or other inquiries please contact bd@nptrapidtesting.com.

Connect with Us on LinkedIn